<DOC>
	<DOCNO>NCT02963675</DOCNO>
	<brief_summary>This study conduct obtain information prostate cancer patient bone metastasis end 2013 . The incidence second primary malignancy overall survival patient castration resistant prostate cancer particular interest . Information study serve historical reference REASSURE study ( Background incidence study )</brief_summary>
	<brief_title>Incidence Second Primary Malignancies Prostate Cancer Patients With Bone Metastases - Observational Retrospective Cohort Study Sweden</brief_title>
	<detailed_description>Prostate cancer ( PC ) common non-cutaneous malignancy men . Once become metastatic , pose serious threat patient ' quality life survival . The common site metastasis skeletal system : Among castration-resistant prostate cancer patient bone metastasis involve 90 % metastatic case . The development new treatment lead improved quality life prolong lifetime among castration-resistant prostate cancer patient metastasis ( mCRPC ) . A recent randomized clinical trial indicate significant improvement survival quality life among patient bone metastasis treat alpha emitter radium-223 compare placebo . To evaluate safety profile Radium-223 patient castration resistant prostate cancer bone metastasis , Radium-223 alpha Emitter Agent non-intervention Safety Study mCRPC popUlation long-teRm Evaluation ( REASSURE study ) , international prospective observational single-arm cohort study implement post-marking requirement request U.S. Food Drug Administration ( FDA ) European Medicines Agency ( EMA ) . In case new treatment improve length quality life substantially , challenge obtain appropriate comparison group post-authorization phase . This study conduct obtain information prostate cancer patient bone metastasis end 2013 . The incidence second primary malignancy overall survival particular interest . Information study serve historical reference REASSURE study</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>mPC population ; follow criterion fulfil : A . ) PC diagnosis 1.1.1998 31.12.2011 B . ) Bone metastases diagnosis 1.1.1999 31.12.2011 mCRPC population ; follow criterion fulfil : 1 . PC diagnosis 1.1.1998 31.12.2011 2 . Bone metastases diagnosis 1.1.2007 31.12.2011 3 . One follow 1.1.2006 31.12.2011 time bone metastases diagnosis : 1 . Discontinuation initial chemical castration ( androgen deprivation therapy , ADT ) , change agent modality ADT , start treatment advanced PC primary ADT ( include chemotherapy mitoxantrone ) 2 . Surgical castration initiation ADT treatment , chemotherapy mitoxantrone afterwards 3 . Treatment medication specific either castrationresistant PC mCRPC ( cabazitaxel , enzalutamide abiraterone ) . 4 . In sensitivity analysis , also least 6 month since initiation castration treatment cohort entry date ( bone metastases diagnosis ) include mCRPC population . First PC diagnosis later 2 month diagnosis bone metastasis , Permanent residence Sweden patient otherwise contribute register least year diagnosis bone metastasis ( patient count contribute also database existence less year cohort entry ) , Use radiopharmaceuticals bone metastasis ( ATC code ) : Samarium ( V10BX02 ) , strontium ( V10BX01 ) , rhenium ( V10BX03 ) radium ( V10XX03 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>